Increased β-catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach

CHUNHUI LIU1, YOUTU WU2, SHENGYUAN YU2, JIWEI BAI1, CHUZHONG LI2, DAN WU3 and YAZHUO ZHANG1,2

1Neurosurgical Department, Beijing Tiantan Hospital; 2Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050; 3Neurological Department, Beijing Renhe Hospital, Beijing 102699, P.R. China

Received December 12, 2015; Accepted December 8, 2016

DOI: 10.3892/mmr.2017.6169

Abstract. Non-functional pituitary adenomas (NFPAs) account for 80% of pituitary adenomas with the majority of these exhibiting recurrences post-surgery. Overexpression of β-catenin and c-myc is common in numerous invasive tumors. The present study sought to investigate the correlation of β-catenin and c-myc expression levels with aggressive growth and recurrence of NFPAs, using immunohistochemical examination of tissue microarrays. Tissue microarrays comprised 212 NFPAs specimens and 10 healthy specimens as controls. NFPAs were categorized as non-aggressive or aggressive. Immunohistochemical examination was performed to determine the expression of β-catenin and c-myc. Correlation of the expression levels of β-catenin and c-myc with clinicopathological parameters, including aggressiveness and recurrence, were assessed by univariate, multivariate and logistic regression analysis. Increased expression of β-catenin and c-myc was detected in the majority of aggressive NFPAs specimens (71.1% and 88.7%, respectively). There was a significant positive correlation between β-catenin and c-myc expression and aggressiveness [P=0.001, Odds Ratio (OR)=4.011; P<0.001, OR=30.833]. Only β-catenin expression demonstrated a significant correlation with recurrence in NFPAs (P=0.021, OR=2.571). β-catenin and c-myc were demonstrated to be potential biomarkers for aggressive NFPAs and in the future, β-catenin may serve as a marker for aggressive behavior and recurrence in NFPAs.

Introduction

Pituitary adenoma (PA), the third most frequently diagnosed intracranial tumor, accounts for <10-25% of all primary intracranial tumors (1). Although the majority of PAs are benign, several of them exhibit an aggressive behavior characterized by rapid cell growth and involvement of the contiguous structures. Based on the signs and symptoms secondary to the over-secretion of pituitary hormones by the tumor, PA is classified into two major groups: functional pituitary adenomas (FPAs) and non-FPAs (NFPAs). The latter accounts for 80% of pituitary macroadenomas (2). Although surgery is the primary option for treatment, NFPAs frequently have supra- or parasellar extension, due to which total resection of tumor is often not possible. The residual tumor regrows in 12-58% of patients within a span of 5 years (3). The complex tumor pathology of NFPAs has served as a barrier to the development of effective therapeutic interventions. Identification of markers that can predict aggressive characteristics of NFPAs may aid in the treatment strategy and be of assistance in preventing recurrence.

Wnt signaling is known to regulate cell proliferation, polarity and cell death (4). Aberrant Wnt signal transduction pathway has been implicated in tumorigenesis and tissue invasion (5). Activation of the Wnt-β-catenin pathway results in the abnormal accumulation of free β-catenin in the nuclei of cancer cells. This in turn activates transcription factors such as T-cell factor, to induce the expression of target genes involved in cell proliferation, including c-myc (6). In addition to functioning as a transcriptional coactivator, β-catenin is known for its role as a cell adhesion protein (7). β-catenin links E-cadherin molecules to α-catenin leading to strong cadherin-mediated cell adhesion (8). Aberrant expression of β-catenin has a role in cellular transformation, tissue invasion and metastasis (7).

c-myc is a potent oncogene that has been demonstrated to promote tumorigenesis in a wide range of tissues (9). Upregulated expression of c-myc in tumor cells occurs through several mechanisms, including gene amplification, chromosomal translocation, single nucleotide polymorphism in regulatory regions, mutation of upstream signal pathways and
those that enhance the protein stability (10). This upregulation has a number of consequences in cancer cell biology (11).

Previous studies (12,13) have demonstrated the over-activation of the Wnt-signal pathway in NFPA9. A previous study (14) using gene expression microarrays indicated that β-catenin and c-myc proteins were highly upregulated in NFPA9 compared with normal pituitary tissues. In a subsequent study (12), reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis were used to confirm the overexpression of the two proteins in aggressive NFPA9.

In the present study, the expression levels of β-catenin and c-myc proteins in NFPA9 were investigated using immunohistochemical examination of tissue microarrays to assess their relevance as markers for predicting aggressiveness and recurrence of NFPA9.

Materials and methods

Subjects. A total of 212 NFPA9 specimens resected by trans-sphenoidal surgery from patients (age range, 24-75 years) between 2010 and 2012, were obtained from the Beijing Tiantan Hospital (Beijing, China). The specimens were classified into two groups; non-aggressive and aggressive. A total of 10 normal pituitary glands were obtained from a donation program and served as controls. The deceased donors comprised 6 males and 4 females, aged 21-45 years (mean, 35 years) and had succumbed to non-neurological diseases. NFPA9 and control samples were embedded in paraffin wax to make archival blocks to be used for tissue microarray (TMA). Prior to enrollment, written informed consent was obtained from all NFPA9 subjects. The study was approved by the Ethics Committee at Beijing Tiantan Hospital. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All the cases met the following criteria: i) Each paraffin block contained a sufficiently sized specimen to enable the construction of TMAs; ii) no radiation therapy was administered prior to surgery; iii) clinical information, including endocrinological evaluation and imaging data, was available; and iv) complete follow-up data for a minimum of 3 years.

The biological behavior was assessed according to pre-operative magnetic resonance imaging (MRI)/computed tomography scanning. Aggressive adenomas were defined as fulfilling any of the following two conditions: i) Hardy classification grade III and IV (15); ii) Knosp classification grade III and IV (16).

Clinical and follow-up data. All patients were diagnosed based on pre-operative sella MRI and postoperative pathology. Postoperative sella MRI scans were performed within 72 h post-surgery to determine the remaining residual tumor. These were evaluated by two neuroradiologists and a neurosurgeon, all of whom were blinded to the patient characteristics. The follow-up data for each patient was obtained at 6-month intervals for the first 2 years. Tumor recurrence was investigated by serial sella MRI scans performed at one year following surgery, or in the event of recurrence of clinical symptoms, whichever was the earlier. Recurrence was defined as the presence of a new tumor in patients with total tumor resection, based on the first post-operative MRI scan, or evidence of new growth of an incompletely resected tumor on serial post-operative MRI scans compared with the immediate post-operative MRI scan. The follow-up data were collected for 3 years.

TMA construction. To check the quality of the tissues, 4-µm thick sections of paraffin-embedded tissue from the 212 NFPA9 specimens and the 10 control samples were stained with hematoxylin and eosin (H&E). Three core biopsies of 2.0 mm diameter were selected from each sample and transferred to tissue microarrays using the Leica BOND-III fully automated arrayer (Leica Biosystems, Inc., Lincolnshire, IL, USA). The locations of the core samples were randomly ordered and blinded to the pathologist with regard to the identity on the TMA slides. In addition, 4-µm thick sections of TMAs were obtained using a serial microtome and applied to positively-charged glass slides. The slides were heated in a water bath at 50˚C and subsequently dewaxed and then rehydrated through graded alcohols. The slides were dried at room temperature for 24-48 h and stored at -80˚C for subsequent use. To minimize loss of antigenicity, TMA slides were processed within a week.

Immunohistochemistry (IHC). The tumor content and quality of all TMA slides were evaluated in advance with H&E staining. The TMAs were placed in the Leica BOND-III, which is a fully automated, random and continuous access slide-staining system that processes IHC tests simultaneously. Primary antibodies for β-catenin (1:100, cat. no. ab22656) and c-myc (1:100, cat. no. ab32072) (both from Abcam, Cambridge, UK) were used. The optimal titers of the primary antibodies for the remainder were determined on pre-experimental results. The slides were scanned into digital images using Aperio AT2 (Leica Biosystems, Inc.), then scored for staining positivity and intensity. A total of two neuropathologists, who were blinded to the clinical information of the patients, independently examined and scored each case. Differences in interpretation were resolved by a consensus.

Evaluation of immunohistochemical examination. The β-catenin staining was observed in the nucleus and c-myc staining in the cytoplasm and nucleus. The results were calculated using Aperio AT2 (v12.1.0.5029; Leica Biosystems, Inc.) with digital slide viewing software. The staining intensity for β-catenin and c-myc was scored as follows: 0, no; 1, weak; 2, moderate and 3, high intensity. The distribution of positively stained cells was scored on a scale of 0-5 with 0 for no staining; 1, <20%; 2, 20-40%; 3, 40-60%; 4, 60-80% and 5, 80-100%. The composite score was calculated as the staining intensity score x distribution score (score ≤6, weak expression; >6, strong expression).

Statistical analysis. The chi-square test ($\chi^2$; $P$-value) was used to determine the significance of the association between β-catenin expression, c-myc expression and clinical parameters that included aggressiveness and recurrence. Variables demonstrating a significant association with NFPA recurrence on univariate analysis were additionally subjected to multivariate analysis. Two-tailed $P<0.05$ was considered to indicate a statistically significant difference. Survival rates
were determined using logistic regression analysis. Analyses were performed using SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

**Clinical and pathological features.** All 212 NFPA samples met the inclusion criteria. The details of their clinicopathological parameters are presented in Table I. At the time of the first surgical treatment, the age of the patients ranged between 24-75 years (mean, 50 years; median, 52 years). There were more male patients (n=124, 58.5%) compared with female patients (n=88, 41.5%). The aggressive group (n=97) comprised 41 (42.3%) females and 56 (57.7%) males, while the non-aggressive group (n=115) comprised 47 (40.9%) females and 68 (59.1%) males. Partial resection or minimum residual tumor was identified in 130 (61.3%) of the total patients.

**Tissue microarrays analysis; correlation of β-catenin and c-myc expression with aggressive behavior.** TMA analysis to determine the correlation between β-catenin and c-myc expression in NFPA samples was determined by the immunohistochemical examination of TMA slides (Figs. 1 and 2). The score of β-catenin and c-myc staining in the normal pituitary tissues was significantly low compared with that in the non-aggressive (1.6±0.27 vs. 5.430.27; P=0.001) and aggressive tumors (1.6±0.27 vs. 9.18±0.41, P<0.001). Similar results were observed with c-myc staining, where normal group demonstrated lower expression compared with the non-aggressive (1.6±0.27 vs. 5.57±0.29, P=0.001) and aggressive tumors (1.6±0.27 vs. 9.8±0.43, P<0.001), respectively. The association of protein expression with aggressive behavior was evaluated by the composite score of β-catenin and c-myc staining; ~71.1% of aggressive NFPA displayed strong β-catenin staining (P<0.01), and ~88.7% c-myc overexpression (P<0.001; Table II). However, of 115 non-aggressive NFPA 69 (60%) displayed weak β-catenin and 91 (70.1%) weak c-myc staining.

Univariate analysis of the clinical characteristics indicated a significant correlation between β-catenin and c-myc expression and aggressive behavior (P=0.001 and P<0.001; Table II). There was, in addition, a significant association between β-catenin and c-myc expression (P=0.004; Table II). However, the upregulation of the two proteins was not significantly associated with age, gender or tumor subtype (data not shown; Table II). Furthermore, multivariate analysis indicates a significant association between the overexpression of β-catenin alone with the aggressive behavior of tumors (P<0.001; OR=4.011). There was no significant correlation between the expression of β-catenin with c-myc (P<0.762; OR=1.127).

Univariate analysis identified a significant association between the expression of β-catenin and c-myc and aggressive behavior (P<0.001; Table II). No significant association with other clinicopathological parameters was observed (Table II). In the multivariate analysis, c-myc (P<0.001, OR=30.833) and β-catenin (P<0.001, OR=4.011) were significantly associated with aggressive NFPA (Table II).

**Recurrence-free survival analysis.** Follow-up data were available for all 212 patients. The patients were followed for 42 months. During follow-up, 41 (19.3%) patients experienced tumor recurrence (Table I). Univariate analysis indicated positive β-catenin staining (P=0.002) and tumor aggressiveness (P=0.004) to be significantly associated with recurrence, while other clinicopathological parameters and positive c-myc staining were not associated with NFPA recurrence (Table III). Additional multivariate analysis identified a significant association between recurrence and β-catenin expression (P=0.021; OR=2.571) and with tumor aggressiveness (P=0.043; OR=2.158; Table III).

**Discussion**

Aggressive behavior of tumors is the most important prognostic factor in patients with NFPA. Complications of surgery, inability to achieve remission and inadequate therapy are problems associated with aggressiveness (17). There is no effective medical treatment for NFPA, although post-operative radiotherapy is recommended for treatment of residual tumor and to prevent recurrence (18). Predicting the aggressive behavior of NFPA may be a key contribution for therapeutic approaches and prognostic evaluation. In a previous study (2), the Wnt signaling pathway was demonstrated to be involved in tumorigenesis of aggressive NFPA; RT-qPCR and western blotting analysis demonstrated overexpression of β-catenin and its downstream signal target c-myc in aggressive NFPA. The proteins β-catenin and c-myc are considered to be useful markers of tumor progression in different types of solid tumors (19-23).

Until now, there has been no reported correlation of β-catenin and c-myc with different clinicopathological
Table II. Univariate and multivariate analyses for clinical and pathologic variables related to aggressive non-functioning pituitary adenomas.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Aggressiveness n (%)</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n=97)</td>
<td>No (n=115)</td>
<td>χ²</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>56 (57.7%)</td>
<td>68 (59.1%)</td>
<td>0.042</td>
</tr>
<tr>
<td>Female</td>
<td>41 (42.3%)</td>
<td>47 (40.9%)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;52</td>
<td>51 (52.6%)</td>
<td>52 (45.2%)</td>
<td>1.141</td>
</tr>
<tr>
<td>≥52</td>
<td>46 (47.4%)</td>
<td>63 (54.8%)</td>
<td></td>
</tr>
<tr>
<td>Subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Null cell</td>
<td>69 (71.1%)</td>
<td>79 (68.7%)</td>
<td>3.708</td>
</tr>
<tr>
<td>Gonadotroph</td>
<td>9 (9.3%)</td>
<td>17 (14.8%)</td>
<td></td>
</tr>
<tr>
<td>Silent corticotroph</td>
<td>4 (4.1%)</td>
<td>1 (0.9%)</td>
<td></td>
</tr>
<tr>
<td>Silent 3</td>
<td>15 (15.5%)</td>
<td>18 (15.6%)</td>
<td></td>
</tr>
<tr>
<td>β-catenin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>28 (28.9%)</td>
<td>69 (60%)</td>
<td>20.55</td>
</tr>
<tr>
<td>Strong</td>
<td>69 (71.1%)</td>
<td>46 (40%)</td>
<td></td>
</tr>
<tr>
<td>c-myc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>11 (12.3%)</td>
<td>91 (70.1%)</td>
<td>96.861</td>
</tr>
<tr>
<td>Strong</td>
<td>86 (88.7%)</td>
<td>24 (20.9%)</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval.

Figure 1. Immunohistochemical study showing expression of β-catenin tissue microarray. A-a (magnification, x1), A-b (magnification, x100), A-c (magnification, x400): Weak β-catenin-positive cells representative of normal pituitary tissues. B-a (magnification, x1), B-b (magnification, x100), B-c (magnification, x400): Weak β-catenin-positive cells representative of non-aggressive NFPAs. C-a (magnification, x1), C-b (magnification, x100), C-c (magnification, x400): Strong β-catenin-positive cells representative of aggressive NFPAs. NFPA, non-functioning pituitary adenoma.

parameters in NFPAs. The present study may be the first of its type to investigate this association; it studied the correlation of β-catenin and c-myc proteins with aggressiveness in NFPAs using IHC on tissue microarrays. The data demonstrated that
β-catenin and c-myc expression was increased in the aggressive NFPAs compared with the non-aggressive NFPAs and the normal pituitary tissues. On univariate analysis of β-catenin and c-myc expression, no statistical correlation was observed with respect to the clinicopathological parameters. However, they demonstrated a positive correlation with only aggressive behavior. Thus, β-catenin and c-myc can be used as biological markers for the detection of aggressive NFPAs. The results of the present study are consistent with those reported for other types of cancer. β-catenin and c-myc expression were upregulated in poor histological grade gastric cancers (24) and β-catenin expression was associated with higher grades in breast phyllodes tumors (25). The increased expression of c-myc was observed at a relatively late stage during progression in prostate cancer and it was demonstrated to correlate with tumor invasion and metastasis (26). Although a previous study reported the correlation of invasion with silent subtype 3 adenomas (26), no such clinicopathological association was identified by the present study.

The reported recurrent rates vary between different studies due to the difference in follow-up period and the number of patients enrolled (27,28). In the present study, with a follow-up period of 42 months, the mean of recurrence was 19.3% (41/212) (Table I), which is marginally lower than previously reported (20-30%). The follow-up period in these studies ranged between 2 months and 24 years (27,29). This difference could be associated with the shorter follow-up in the present study and the variability in the definition of recurrence/progression.

Table III. Univariate and multivariate analyses for clinical and pathological variables associated with recurrence/progression-free survival.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Recurrence (within 42 months)</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n=41)</td>
<td>No (n=171)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>χ²</td>
<td>P-value</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23 (56.1%)</td>
<td>101 (59.1%)</td>
<td>0.77</td>
</tr>
<tr>
<td>Female</td>
<td>18 (43.9%)</td>
<td>70 (40.9%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;52</td>
<td>23 (56.1%)</td>
<td>108 (63.2%)</td>
<td>3.124</td>
</tr>
<tr>
<td>≥52</td>
<td>18 (43.9%)</td>
<td>63 (36.8%)</td>
<td></td>
</tr>
<tr>
<td>Subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Null cell</td>
<td>29 (70.7%)</td>
<td>119 (69.6%)</td>
<td>2.709</td>
</tr>
<tr>
<td>Gonadotroph</td>
<td>6 (14.6%)</td>
<td>20 (11.7%)</td>
<td></td>
</tr>
<tr>
<td>Silent corticotroph</td>
<td>2 (4.9%)</td>
<td>3 (1.8%)</td>
<td></td>
</tr>
<tr>
<td>Silent 3</td>
<td>4 (9.8%)</td>
<td>29 (16.9%)</td>
<td></td>
</tr>
<tr>
<td>Aggressiveness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>27</td>
<td>70</td>
<td>8.273</td>
</tr>
<tr>
<td>No</td>
<td>14</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>β-catenin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>10 (24.4%)</td>
<td>87 (50.9%)</td>
<td>9.348</td>
</tr>
<tr>
<td>Strong</td>
<td>31 (75.6%)</td>
<td>84 (49.1%)</td>
<td></td>
</tr>
<tr>
<td>C-myc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>16 (39.1%)</td>
<td>85 (49.7%)</td>
<td>1.682</td>
</tr>
<tr>
<td>Strong</td>
<td>25 (60.9%)</td>
<td>86 (50.3%)</td>
<td></td>
</tr>
<tr>
<td>Surgical extent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross total resection</td>
<td>13 (31.7%)</td>
<td>69 (40.4%)</td>
<td>1.042</td>
</tr>
<tr>
<td>Residual</td>
<td>28 (68.3%)</td>
<td>102 (59.6%)</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval.

The multivariate analysis demonstrated that an increased IHC positivity of β-catenin is a strong predictive factor of tumor recurrence. Although c-myc demonstrated a significant
LIU et al: β-CATENIN AND c-myc AS BIO-MARKERS FOR AGGRESSIVE NFPA

...correlation with aggressive NFPA, no other association of c-myc with recurrence was observed.

The observation that tumor resection is not associated with tumor recurrence is in agreement with the results reported by Brochier et al (3). They also reported that surgical extent is not an independent factor of recurrence in pituitary adenoma (31). This observation is in contrast to the results of previous studies (30,31) that indicated tumor resection was a predictive factor for the recurrence of PA. The reason for this discrepancy in results can be attributed to combination of different types of PA, the difference in sample size and the length of follow-up duration in these studies, whereas the present study analyzed a homogenous group of NFPA samples. The follow-up data was analyzed using logistic regression analysis instead of the classical Kalpan Meier survival rate analysis. The survival time was not included to avoid discrepancy caused by the low recurrence rate. These may be two reasons for the inconsistency in results. Further studies are required to validate the results of the present study.

In conclusion, the present study suggested that β-catenin and c-myc can be a useful immunohistochemical marker for identifying aggressive NFPA. Only after validation in a large number of samples can β-catenin be used for the prediction of recurrence of NFPA following surgical resection.

Acknowledgements

The present study was supported by the National High-Tech Research and Development Program of China (grant no. 2014AA020610), the National Health and Family Planning Commission for Public Welfare Industry Research Project (grant no. 201402008), the National Natural Science Foundation of China (grant no. 3157060076) and the Natural Science Foundation of Beijing Municipality (grant no. 7144198).

References


